Vertex Pharmaceuticals Inc
Company Profile
Business description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Contact
50 Northern Avenue
BostonMA02210
USAT: +1 617 341-6100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6,100
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,789.40 | 45.80 | 0.52% |
| CAC 40 | 7,691.55 | 134.24 | 1.78% |
| DAX 40 | 24,033.22 | 383.92 | 1.62% |
| Dow JONES (US) | 43,819.27 | 432.43 | 1.00% |
| FTSE 100 | 8,798.91 | 63.31 | 0.72% |
| HKSE | 24,182.95 | 101.20 | -0.42% |
| NASDAQ | 20,273.46 | 105.55 | 0.52% |
| Nikkei 225 | 40,624.59 | 473.80 | 1.18% |
| NZX 50 Index | 12,565.12 | 18.47 | -0.15% |
| S&P 500 | 6,173.07 | 32.05 | 0.52% |
| S&P/ASX 200 | 8,561.40 | 47.20 | 0.55% |
| SSE Composite Index | 3,431.18 | 6.95 | 0.20% |